Htg molecular diagnostics, inc (HTGM)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenue:
Total revenue

18,226

19,203

22,132

21,433

20,548

21,503

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product and product-related services

-

-

-

-

-

-

-

-

-

-

-

6,784

5,903

5,132

2,865

3,333

3,404

3,532

3,160

2,718

2,145

1,788

0

0

0

Collaborative development services

-

-

-

-

-

-

-

-

-

-

-

0

-

-

2,025

1,654

386

183

250

320

344

497

0

0

0

Other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

325

712

943

1,036

1,043

0

0

0

Total revenue

-

-

-

-

-

-

-

-

-

-

-

5,503

5,638

5,132

4,890

4,987

3,882

4,041

4,123

3,982

3,526

3,328

0

0

0

Cost of revenue

-

-

-

-

-

-

-

-

-

-

4,855

4,891

4,587

4,135

3,698

3,382

3,284

3,335

3,738

3,676

3,457

3,204

0

0

0

Gross margin

-

-

-

-

-

-

-

-

-

-

3,457

611

1,050

996

1,192

1,605

598

706

385

306

69

124

0

0

0

Operating expenses:
Cost of product and product-related services revenue

7,881

8,911

8,755

7,056

5,998

5,090

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

18,956

18,682

18,500

18,693

18,717

19,974

19,735

19,284

18,933

17,513

16,994

16,673

16,972

17,427

17,455

17,234

16,248

14,994

13,664

12,557

11,260

9,897

0

0

0

Research and development

10,421

10,570

11,587

12,578

12,083

12,598

12,541

12,458

11,318

9,996

7,748

6,180

7,173

7,900

8,166

7,565

5,907

4,601

3,653

2,993

2,905

3,075

0

0

0

Total operating expenses

37,259

38,163

38,843

38,328

36,800

37,663

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

-

-

-

-

-

-

-

-

-

-

24,742

22,853

24,145

25,328

25,621

24,800

22,156

19,596

17,317

15,550

14,166

12,972

0

0

0

Operating loss

-19,033

-18,960

-16,711

-16,894

-16,252

-16,159

-15,776

-16,073

-17,518

-17,722

-21,285

-22,241

-23,094

-24,331

-24,429

-23,195

-21,558

-18,890

-16,932

-15,244

-14,096

-12,848

0

0

0

Other income (expense):
Loss from change in stock warrant valuation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

239

239

296

0

-

0

0

-

Interest expense

948

957

966

958

953

901

909

975

1,091

1,307

1,494

1,684

1,873

1,867

1,807

1,695

1,632

1,719

1,748

1,531

1,111

706

0

0

0

Interest income

583

623

644

720

763

715

547

374

194

73

71

75

89

112

129

141

121

85

0

0

0

-

-

-

-

Other income

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of Growth Term Loan

-

-

-

-

-

-105

0

0

0

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-13

0

0

0

Total other expense

-342

-334

-322

-237

-189

-291

-466

-705

-1,002

-1,234

-1,418

-1,570

-1,727

-1,698

-1,622

-1,525

-2,764

-2,497

-2,321

0

0

-

0

-

-

Net loss before income taxes

-19,376

-19,294

-19,748

-19,103

0

-

0

0

-

-18,957

-22,704

-23,812

-24,822

-26,029

-26,051

-24,720

-24,322

-21,387

-19,836

-17,986

-15,218

-13,958

0

0

0

Provision for income taxes

0

-

0

0

-

-

-

0

-

2

6

6

6

10

0

0

0

-

-

-

-

-

-

-

-

Net loss

-19,384

-19,297

-17,036

-17,139

-16,444

-16,453

-16,248

-16,785

-18,523

-18,960

-22,711

-23,818

-24,829

-26,039

-26,066

-24,735

-24,336

-21,397

-19,836

-17,986

-15,218

-13,958

0

0

0

Accretion of stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

35

-90

-70

104

102

0

0

0

Accretion of Series E warrant discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

127

0

0

0

-

-

-

0

Accretion of Series D and E redeemable convertible preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,165

0

0

0

-

-

-

-

Accretion of Series D and E redeemable convertible preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-22,726

-21,959

-21,060

-18,974

-17,618

0

0

0

Net loss per share, basic and diluted

-0.08

0.00

-0.15

-0.17

-0.19

-0.07

-0.17

-0.14

-0.22

0.00

-0.46

-0.60

-0.73

-0.74

-0.92

-0.98

-1.02

12.45

-0.76

-1.73

-14.99

-43.47

-44.14

-49.62

-37.80

Shares used in computing net loss per share, basic and diluted

64,567

63,773

31,367

28,657

28,600

28,579

28,434

28,375

24,704

13,045

11,603

9,769

7,971

7,495

7,053

7,018

6,885

6,937

6,829

3,973

333

113

96

96

96

Product and Product-related Services
Total revenue

13,957

14,632

15,447

12,451

10,050

9,121

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaborative Development Services
Total revenue

4,268

4,571

6,684

8,982

10,497

12,382

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-